



Mark Nylan

PARTNER

BOSTON

+ 1 617 526 6405

MARK.NYLEN@WILMERHALE.COM

Mark Nylan is a partner in the Corporate Practice. He regularly counsels both private and public companies on a variety of transactions, including mergers, acquisitions, venture capital financings and joint ventures. Mr. Nylan has significant experience advising both emerging and established companies in the life sciences, technology and financial services industries, among a range of other sectors.

Prior to joining WilmerHale, Mr. Nylan was a corporate associate at another large law firm in New York, where he advised on corporate governance matters and worked on both asset and equity acquisitions as well as mergers across a variety of industries.

Solutions

Capital Markets

Debt Finance

Mergers and Acquisitions

Corporate Governance and Disclosure

Emerging Company and Venture Capital

Technology

Cross-Border Transactions

Life Sciences

Experience

- IMARA, a clinical-stage biopharmaceutical company, in its sale of assets to Cardurion Pharmaceuticals and its subsequent merger with Enliven Therapeutics
- Aileron Therapeutics, a clinical stage chemoprotection oncology company, in its acquisition of Lung Therapeutics, a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments
- Novo Nordisk, a leading global healthcare company, in its strategic collaboration with Flagship Pioneering to create a portfolio of transformational medicines
- Nasdaq Private Market, a leading provider of liquidity solutions to private companies, in its \$62.4 million Series B Financing
- TMX Group, in its strategic investment in VettaFi, a US-based, privately owned data, analytics, indexing, digital distribution, and thought leadership company
- Gemini Therapeutics, a precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration, in its merger with Disc Medicine, Inc., a privately held, clinical-stage biopharmaceutical company
- DriveWealth, a pioneer in fractional investing and embedded finance, in its acquisition of Crypto-Systems, LLC, a company that offers tailored market-making services to platforms for digital assets to provide deep and stable liquidity
- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for immunology, in its \$157 million Series A financing
- Cloud9 Technologies LLC, a leader in integrated cloud-based communication solutions, in its acquisition by Symphony Communication Services Holdings
- Zaius, a customer data platform bringing the context of the customer to the experience creation and optimization process of digital experiences, in its acquisition by Optimizely (formerly Episerver), a leading provider of digital experience platform solutions
- PerkinElmer, a global leader committed to innovating for a healthier world, in its \$591 million acquisition of Oxford Immunotec, a global leader of proprietary test kits for latent tuberculosis

Credentials

EDUCATION

JD, University of Pennsylvania
Law School, 2012

*Associate Editor, Journal of
Business Law*

BA, Communications, Boston
College, 2008

magna cum laude

ADMISSIONS

Massachusetts

New York